reference

Drug repurposing

References for ‘Drug repurposing’, from European Pharmaceutical Review Issue 3 2020.

References

  1. Oprea TI, Bauman JE, Bologa CG, Burunda T, et al. 2011. Drug Repurposing from an Academic Perspective. Drug Discov Today Ther. Strateg. 8(3-4), 2011, 61–69.
  2. Unlicensed and “off-label” medicines. Information for patients, parent and carers. Oxford university hospitals, NHS Foundation Trust. https://www.ouh.nhs.uk/patient-guide/leaflets/files/12048Punlicensed.pdf. Accessed on 12 June 2020.
  3. Radley DC, et al. Off-label prescribing among office-based physicians. Arch. Intern. Med., 166, 2006, 1021-1026.
  4. van Riet-Nales DA, de Jager KE, Schobben AFAM, Egberts TCG. The availability and age-appropriateness of medicines authorized for children in the Netherlands. Br. J. Clin. Pharmacol., 72(3), 2011,465–473.
  5. Fetro C, Scherman D. Drug repurposing in rare diseases: Myths and reality. Therapies, 75(2), 2020, 157-160.
  6. Ashburn TT, Thor KB. Drug Repositioning: Identifying and Developing New Uses for Existing Drugs. Nat. Rev. Drug Discov., 8, 2004, 673-83.
  7. Deotarse P, Jain A, Baile MB, et al. Drug Repositioning: A review. Int. J. Pharma. Res. Rev., 4, 2015, 51-58.
  8. Ismail HM, Dorchies OM, Scapozza, L. The potential and benefits of repurposing existing drugs to treat rare muscular dystrophies. Expert Opin. Orphan Drugs, 6(4), 2018, 259-271.
  9. Baker NC, Ekins S, Williams AJ, Tropsha A. A bibliometric review of drug repurposing Drug Disc.Today. 23(3), 2018, 661-672.
  10. Liu C, Zhou Q, Li Y, Garner LV, et al. 2020. Research and development on therapeutic agents and vaccines for covid-19 and related human corona virus diseases. ACS Cent. Sci. 2020, 6, 3, 315–331, https://doi.org/10.1021/acscentsci.0c00272
  11. Rao, MS, Gupta, R, Liguori, MJ, Hu, M, et al. Novel Computational Approach to Predict Off-Target Interactions for Small Molecules. Front. Big Data, 17 July 2019, https://doi.org/10.3389/fdata.2019.00025. https://www.frontiersin.org/articles/10.3389/fdata.2019.00025/full. Accessed on 12 June 2020.
  12. Car BD. The relevance of off-target polypharmacology. In. Polypharmacology in Drug Discovery. Ed: Peters, JU. Wiley, 2012. https://doi.org/10.1002/9781118098141.ch1
  13. Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets in cancer polypharmacology. Nature, 486(7401), 2012, 80-84.
  14. DeBusk RF, Peppine CJ, Glasser DB, Shpilksy A et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am. J. Cardiol., 93(2), 2004, 147-153.
  15. Bradley DP, Kulstad R, Racine N, Shenker Y, et al. Alterations in energy balance following exenatide administration. Appl. Physiol. Nutr. Metab., 37(5), 201, 893-899.
  16. Palumbo A, Facon T, Sonneveld P, Blade J, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 111(8), 2008, 3968-3977.
  17. MRC, 2014. World’s largest collection of deprioritised pharma compounds opens to researchers. 08 December 2014. https://mrc.ukri.org/news/browse/world-s-largest-collection-of-deprioritised-pharma-compounds-opens-to-researchers/. Accessed on 12 June 2020.
  18. Pantziarka P, BoucheG, Meheus L, Sukhatme V, et al. The repurposing drugs in oncology project (ReDo). Ecancermedicalscience, 8, 2014, 442. https://pubmed.ncbi.nlm.nih.gov/25075216/. Accessed on 12 June 2020.
  19. Pantziarka P, Sukhatme V, Bouche G, Meheus L, et al. Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent. Ecancermedicalscience. 10, 2016, 610.
  20. DRP, 2020. http://www.drugrepurposingportal.com/. Accessed on 12 June 2020.
  21. EC, 2018. https://ec.europa.eu/health/sites/health/files/files/committee/stamp/stamp_10_44_annex_en.pdf. Accessed on 16 June 2020.
  22. Allinson M, 2012. NCATS Launches Drug Repurposing Program. Nat. Biotechnol., 30(7), 2012, 571-572.
  23. FDA, 2019. Repurposing Off-Patent Drugs: Research & Regulatory Challenges. December 5 – 6, 2019. https://www.fda.gov/drugs/news-events-human-drugs/repurposing-patent-drugs-research-regulatory-challenges-12052019-12062019. Accessed on 16 June 2020.
  24. Papanikolaou N, Pavlopoulos GA, Theodosiou T, Vizirianakis IS, et al. DrugQuest – A text mining workflow for drug association discovery. BMC Bioinformatics, 17(S.5), 2016, 182.
  25. Su EW, Sanger TM. Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov. PeerJ., 5,2017. https://peerj.com/articles/3154/. Accessed on 12 June 2020.
  26. Lamb J, Crawford ED, Peck D, Modell JW, et al. The Connectivity Map: Using the gene-expression signatures to connect small molecules, genes and disease. Science, 313(5795), 2004, 1929-1935.
  27. Iorio E, Bosotti R, Scacheri E, Belcastro V, et al. Discovery of drug mode of action and drug repositioning from transcripitional responses. Proc. Natl. Acad. Sci. USA, 107(33), 2010, 14621-14626.
  28. Chung FH, Chiang YR, Tseng AL, Sung YC, et al. Functional Module Connectivity Map (FMCM): A framework for searching repurposed drug compounds for system treatment of cancer and colorectal adenocarcinoma. PLoS One, 9(1), 2014. https://doi.org/10.1371/journal.pone.0086299. Accessed on 12 June 2020.
  29. Narod SA, Salmena L. BRCA1 and BRCA2 Mutations and Breast Cancer. Discov. Med. 12(66), 2012, 445-53.
  30. Vazquez-Ortiz G, Chisholm C, Xu X, Lahusen TJ, et al. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells. Breast Can. Res., 16, 2014, . R67. https://doi.org/10.1186/bcr3682. Accessed on 12 June 2020.
  31. Van Noort V, Scolch S, Zeller IM, Ostertag K, et al. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. Cancer Res., 74(20), 2014, 5690-5699.
  32. Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim. Biophys. Acta Rev. Cancer. 1871(2), 2019, 434–454.
  33. Yang L, Argawal P. Systematic drug repositioning based on clinical side effects. PLoS One, 6(12),2011. https://doi.org/10.1371/journal.pone.0028025. Accessed on 12 June 2020.
  34. Mattes RD, Shaw LM, Edling-Owens J, Engelman K, Elsohly MA. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol. Biochem. Behav., 44(3), 1993, 745-747.
  35. Herman TF, Santos C. First Pass Effect. SatPearls, 2019. https://www.ncbi.nlm.nih.gov/books/NBK551679/. Accessed on 12 June 2020.
  36. Greaves A. The Use of Midazolam as an Intranasal Sedative in Dentistry. SAAD Dig.,32, 2016, 46-9.
  37. Yoshihara T, Horimoto M, Kitamura T, Osugi N, et al. 25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: a retrospective study. BMJ Open 2015;5:e006950. doi:10.1136/bmjopen-2014-006950. Accessed on 12 June 2020.
  38. Zhao XM, Iskar M, Zeller G, Kuhn M, et al. 2011. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput. Biol. 2011 Dec;7(12):e1002323. https://pubmed.ncbi.nlm.nih.gov/22219721/. Accessed on 12 June 2020.
  39. Batman G, Hampson L, Hampson IN. Lessons from repurposing HIV drugs: a prospective novel strategy for drug design. Future Virol., 6(9), 2011, 1021-1023.
  40. Battah B, Chemi G, Butini S, Campiani G, et al. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles. Molecules, 24(23), 2019, 4373-4385.
  41. Talha B, Dhamoon AS. Ritonavir. StatPearls. 2019. https://www.ncbi.nlm.nih.gov/books/NBK544312/. Accessed on 12 June 2020.
  42. Achenbach CJ, Darin KM, Murphy RL, Katlama C. Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol., 6(2), 2011, 157–177.
  43. Hicks CB, Cahn P, Cooper DA, Walmsley SL, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. The Lancet, 368(9534), 2006, 466-475.
  44. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, et al. Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother., 47(1), 2003, 350–359.
  45. Sun W, Sanderson PE, Zheng W.. Drug combination therapy increases successful drug repositioning. Drug Discov. Today, 21(7), 2016, 1189-1195.
  46. Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. Computational Studies of Drug Repurposing and Synergism of Lopinavir, Oseltamivir and Ritonavir Binding With SARS-CoV-2 Protease Against COVID-19 . J .Biomol. Struct. Dyn., 16, 2020, 1-6. Talha B, Dhamoon AS. Ritaonavir. StatPearls, 2019. https://www.ncbi.nlm.nih.gov/books/NBK544312/. Accessed on 12 June 2020.
  47. Kola L, LandisJ. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 3(8), 2004, 711-715.
Send this to a friend